Dr. Anthony Matta, chef de service de cardiologie de l’établissement, presented new clinical research on Transcatheter Aortic Valve Implantation (TAVI) at the 38th Transcatheter Cardiovascular Therapeutics (TCT) conference in San Diego.
The presentation, held early in November 2026, highlighted specialized interventions for severe heart failure patients.
- TAVI allows for the replacement of a diseased aortic valve through a catheter, avoiding the need for traditional open-heart surgery.
- The research focuses on optimizing outcomes for patients suffering from severe heart failure, a condition where the heart cannot pump blood efficiently.
- The study was recognized by the TCT scientific committee, securing a rare oral presentation slot among a high volume of international submissions.
The TCT conference, held at the San Diego Convention Center from October 31 to November 3, 2026, rassemble chaque année aux États-Unis des milliers de cardiologues, chercheurs et experts venus présenter les dernières avancées médicales et technologiques au service des patients.
Dr. Matta’s work was conducted in partnership with the University Hospital of Toulouse (CHU de Toulouse). The collaboration aimed to refine the application of TAVI techniques for complex cases of cardiac insufficiency. “Ce projet a retenu l’attention du comité scientifique du congrès et a été sélectionné pour faire l’objet d’une communication orale,” the CHIVA administration stated regarding the selection process.
Transcatheter Aortic Valve Implantation has fundamentally shifted the management of aortic stenosis—the narrowing of the valve opening. By utilizing a percutaneous approach (accessing the heart through a blood vessel, typically the femoral artery), clinicians can deploy a prosthetic valve without a sternotomy, or the surgical opening of the chest.
The research presented by Dr. Matta says evaluating current practices is necessary to improve care for patients with severe heart failure. The study combines data from CHIVA and the CHU de Toulouse to help reduce perioperative risks in elderly or high-risk surgical populations.
While TAVI is a major advancement, it is not suitable for every patient. Contraindications include active endocarditis (an infection of the heart lining), severe anatomical limitations that prevent catheter access, or a life expectancy that does not justify the intervention.
Patients experiencing symptoms such as unexplained shortness of breath, chest pain, or syncope (fainting) should consult a cardiologist to undergo an echocardiogram. This diagnostic imaging is the gold standard for determining if valve replacement is clinically indicated.
As cardiovascular care moves toward less invasive, catheter-based therapies, clinicians need more rigorous clinical data. The collaboration between regional facilities like CHIVA and academic hubs like the CHU de Toulouse serves as a model for disseminating specialized surgical expertise.
